Paper2201397
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
Shearer RJ and 6 others. Br J Cancer, 1990. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Aromatase inhibition in advanced prostatic cancer: preliminary communication. Papers, record 2201397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2201397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aromatase Inhibitors | Major topic |
| Prostatic Neoplasms | Major topic |
| Aged | |
| Aged, 80 and over | |
| Androstenedione | |
| Antineoplastic Agents | |
| Clinical Trials as Topic | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5963388 | A new oral progestational steroid effective in treating prostatic cancer. | Trans Am Assoc Genitourin Surg | 1966 | https://conductscience.org/library/papers/5963388 | PubMed |
| 2 | 109413 | Actions of estrogen in the male. | Invest Urol | 1979 | https://conductscience.org/library/papers/109413 | PubMed |
| 3 | 7336466 | Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. | Steroids | 1981 | https://conductscience.org/library/papers/7336466 | PubMed |
| 4 | 6180250 | Failure of human benign prostatic hyperplasia to aromatise testosterone. | J Steroid Biochem | 1982 | https://conductscience.org/library/papers/6180250 | PubMed |
| 5 | 6827685 | Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. | J Urol | 1983 | https://conductscience.org/library/papers/6827685 | PubMed |
| 6 | 6238616 | Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6238616 | PubMed |
| 7 | 3358910 | The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. | Br J Cancer | 1988 | https://conductscience.org/library/papers/3358910 | PubMed |
| 8 | 3155636 | Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. | Br Med J (Clin Res Ed) | 1985 | https://conductscience.org/library/papers/3155636 | PubMed |
| 9 | 4084734 | Is delayed treatment justified in carcinoma of the prostate? | Br J Urol | 1985 | https://conductscience.org/library/papers/4084734 | PubMed |
| 10 | 2431401 | Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. | Prostate | 1986 | https://conductscience.org/library/papers/2431401 | PubMed |
| 11 | 2433507 | Aromatase inhibitors and benign prostatic hyperplasia. | J Steroid Biochem | 1986 | https://conductscience.org/library/papers/2433507 | PubMed |
| 12 | 3815384 | Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. | Cancer Res | 1987 | https://conductscience.org/library/papers/3815384 | PubMed |
| 13 | 3567487 | Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. | Br J Urol | 1987 | https://conductscience.org/library/papers/3567487 | PubMed |
| 14 | 6150277 | 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. | Lancet | 1984 | https://conductscience.org/library/papers/6150277 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7680986 | Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. | Drugs | 1993 | https://conductscience.org/library/papers/7680986 | PubMed |
| 1637664 | Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. | Br J Cancer | 1992 | https://conductscience.org/library/papers/1637664 | PubMed |
| 1493356 | Aromatase inhibitors in malignant diseases of aging. | Drugs Aging | 1992 | https://conductscience.org/library/papers/1493356 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP19A1 | 1588 | PubTator's text mining | https://conductscience.org/library/genes/1588 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2201397
GET https://conductscience.org/api/papers/v1/2201397/authors